S-1/A: Alpha Cognition Files Amendment No. 1 to Form S-1 Registration Statement for Resale of Common Shares

Alpha Cognition has filed an amendment to its registration statement for the offering and resale of up to 42,676,511 common shares by selling stockholders.

Summary

• Alpha Cognition Inc., a biopharmaceutical company focused on neurodegenerative diseases, has filed Amendment No. 1 to its Form S-1 registration statement.
• The amendment pertains to the offering and resale of up to 42,676,511 common shares by selling stockholders, who acquired these shares through private placements between August 2023 and January 2024.
• The company will not receive any proceeds from the sale of these shares.
• Alpha Cognition's common shares are traded on the CSE under the symbol ACOG and on the OTCQB under the symbol ACOGF.
• As of May 9, 2024, the last reported sale price on the CSE was C$0.69, and the last quoted price on the OTCQB was $0.4985.
• The company is an emerging growth company and a smaller reporting company, allowing it to comply with certain reduced public company reporting requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While it highlights the company's progress in developing ALPHA-1062 and its potential market opportunities, it also acknowledges significant risks and uncertainties, including the need for additional funding and the competitive landscape.

Positives

• The company has a Prescription Drug User Fee Act (PDUFA) goal date of July 27th, 2024, for ALPHA-1062.
• The company has filed a new composition-of-matter patent that secures broad protection for its lead asset, ALPHA-1062, currently under review by the FDA for mild-to-moderate Alzheimers Disease.
• The company has a strong executive team with experience in drug approvals and commercial launches.

Negatives

• The company is a pre-commercial stage biopharmaceutical company with no products approved for commercial sale and has incurred significant losses since its inception.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company will need substantial additional capital to meet its financial obligations and to pursue its business objectives.
• The company's business is heavily dependent on the successful development, regulatory approval and commercialization of ALPHA-1062 and any future product candidates that it may develop or acquire.
• The company faces significant competition in an environment of rapid technological and scientific change.

Risks

• The company may not be able to raise capital when needed, which could force it to delay, reduce, or eliminate research and development programs or commercialization efforts.
• Clinical trials may be delayed or terminated for various reasons, including regulatory disagreements, patient enrollment issues, or safety concerns.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or quality control issues.
• The company may face product liability lawsuits, which could result in substantial liabilities.
• The company's stock price may be volatile, and investors may not be able to resell shares at or above the price they paid.
• The company may be a passive foreign investment company (PFIC) under United States tax laws, which could have adverse tax consequences for U.S. investors.

Future Outlook

The company plans to continue advancing its development and commercialization activities for ALPHA-1062 in mild-to-moderate Alzheimers disease and pursue the out-licensing of its TBI indication to Alpha Seven.

Industry Context

The document highlights the competitive landscape in the neurodegenerative disease treatment market, particularly for Alzheimer's disease, where there are limited treatment options and significant unmet needs. The company aims to address these needs with its ALPHA-1062 product candidate.

Comparison to Industry Standards

• The document mentions existing treatments for Alzheimer's disease, such as donepezil, rivastigmine, galantamine, and memantine, and compares ALPHA-1062 to these treatments.
• It also references Biogen's Aduhelm and Eisai's Leqembi as disease-modifying therapeutic options.
• The document notes that current acetylcholinesterase inhibitor medications are associated with gastrointestinal side effects, which ALPHA-1062 aims to minimize.

Stakeholder Impact

• Shareholders: Potential dilution from future financings.
• Employees: Job security dependent on company's financial stability and success of ALPHA-1062.
• Patients: Potential for a new treatment option for Alzheimer's disease.
• Suppliers: Continued business relationship dependent on company's financial health.

Next Steps

• Respond to regulatory questions and inquiries from FDA in a satisfactory manner and negotiate the commercial label and approval of the product with FDA, which is anticipated in Q3 2024.
• Continue development activities and commercialization preparations around ALPHA-1062.
• Complete the out-license the TBI asset into Alpha Seven where Alpha Seven plans to raise the additional capital to advance the TBI program.

Key Dates

Keywords

Alpha Cognition, Common Shares, Registration Statement, Selling Stockholders, ALPHA-1062, Alzheimers Disease, Biopharmaceutical, Private Placement, FDA, ACOG, ACOGF